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CONTEXT: Many treatments aim to improve patients’
health-related quality of life (HRQoL), and many care
guidelines suggest assessing symptoms and their im-
pact on HRQoL. However, there is a lack of consensus
regarding which HRQoL outcome measures are appro-
priate to assess, and how much change on those
measures depict significant HRQoL improvement.
OBJECTIVE: We used triangulation methods to identify
and understand clinically important differences (CIDs)
for the amount of change in HRQoL that reflects both
health professionals and patients’ values, among
patients with chronic obstructive pulmonary disease
(COPD).
DESIGN, SETTING, AND PARTICIPANTS: We incorpo-
rated three perspectives: (1) an expert panel of physi-
cians familiar with the measurement of HRQoL in
COPD patients; (2) 610 primary care COPD outpatients
who completed baseline and bimonthly follow-up
HRQoL interviews over the 12-month study; and (3) the
primary care physicians (PCPs; n=43) of these out-
patients who assessed their patients’ disease at
baseline and at subsequent PCP visits during the year
long study.
MEASUREMENTS: The Chronic Respiratory Disease
Questionnaire (CRQ), the Medical Outcomes Study
Short Form 36-item survey (SF-36, version 2.0), and
global assessments of change from each of the three
perspectives for all HRQoL domains.
RESULTS: With few exceptions, the CRQ was able to
detect small changes at levels reported by the patients
(1–2 points) and their PCPs (1–5 points). These results
confirm minimal important difference standards devel-
oped in 1989 by Jaeschke et al. anchored on patient-
perceived changes in HRQoL. In general, the expert
panel and PCP CIDs were larger than the patient CIDs.
CONCLUSION: This triangulation methodology yielded
improved interpretation, understanding, and insights
on stakeholder perspectives of CIDs for patient-reported
outcomes.
KEY WORDS: health-related quality of life; minimal important
difference; chronic obstructive pulmonary disease.
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INTRODUCTION
The Food and Drug Administration (FDA) recently released a
report titled “Innovation or Stagnation: Challenges and Oppor-
tunities on the Critical Path to New Medical Products.” This
report focused on the current deceleration of innovative and
pioneering medical therapies capable of reaching the patients
who might benefit,
1 and states that:
For many therapeutics, effectiveness criteria are best
defined by the practitioners and patients who use the
products. Much work needs to be done on clinical
trial design and patient-driven outcome measures to
ensure that endpoints in new therapeutic areas
accurately reflect patient needs and values. Commu-
nity (health professional and patient) consensus on
appropriate outcome measures and therapeutic
claims can lay a clear development path for new
therapeutics, especially when there is international
regulatory harmonization. (p. 24)
Although a sound understanding of the biomechanisms of
potentially beneficial medical therapies will always be of great
importance, most medical treatments aim to improve patients’
symptoms and/or functioning and their effects on health-
related quality of life (HRQoL). Whereas it is generally recog-
nized that patient-reported outcomes are relevant, there is no
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161consensus regarding which HRQoL outcome measures are
appropriate to assess HRQoL and how much change on those
measures depicts significant improvement in HRQoL. The
clinically important difference (CID) reflects the amount of
change (either improvement or decline) in HRQoL that is
meaningful to patients and/or their health care providers.
Although some researchers and practitioners will argue that
only the patient’s perspective
2 should inform what constitutes
a meaningful change, it is clear that the FDA has determined
that decisions on which measures to use and what CID
thresholds constitute small, moderate, and large changes in
HRQoL should reflect both health professionals and patients’
needs and values.
1
In 1989 Jaeschke et al.
3 described a minimal clinically
important difference (MCID) in HRQoL as “the smallest differ-
ence in a score of a domain of interest that patients perceive to
be beneficial and that would mandate, in the absence of
troublesome side effects and excessive costs, a change in the
patient’s management.” We view CIDs as an expansion of the
1989 term because the CIDs recognize that within a disease
condition, unique treatment options can have different risks.
Therefore, a patient and clinician may seek a moderate or large
CID in HRQoL if the investment and/or risk of a treatment is
greater than minimal. Hence, CIDs examine the amount of
change associated with a small, moderate, and large improve-
ment or decline in HRQoL. Another popular term for interpret-
ing the magnitude of HRQoL change scores is minimal
important difference, and is generally linked to the smallest
change in HRQoL that is important to patients.
2
With the support of the Agency for Healthcare Research and
Quality, we conducted a 4-year clinical investigation to develop
criteria for assessing HRQoL in patients with chronic obstruc-
tive pulmonary disease (COPD) that could be used to evaluate
therapies. Treatment goals for COPD patients focus on en-
hancing functioning, relieving dyspnea and other symptoms,
improving emotional difficulties, and mastering situations that
may irritate this condition.
4 Therefore, we determined CID
thresholds for both a well-known disease-specific HRQoL
instrument, the Chronic Respiratory Disease Questionnaire
(CRQ)
5 and the most widely used generic measure of HRQoL,
the Medical Outcomes Study Short Form 36-item survey (SF-
36, version 2.0).
6
We selected these two instruments for specific reasons. The
CRQ was developed in 1987 by Guyatt et al.
5 to measure the 4
important HRQoL domains associated with COPD: dyspnea,
fatigue, emotional functioning, and mastery (feelings of control
over of the disease). The items foreach of these domains use a 7-
point scale, and there are 5, 4, 7, and 4 items for the respective
domains. Hence, scores range from 5 to 35 in the dyspnea
domain, 4 to 28 in the fatigue, 7 to 49 in emotional functioning,
and 4 to 28 in mastery. A unique feature of the dyspnea domain
is that each patient identifies 5 activities that are affected by
Figure 1. Expert panel selection, Delphi, and consensus process.
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each of these patient-specific activities across the time of their
enrollment. We chose the CRQ instrument because of (1) the
repeated demonstration of its validity among patients with
chronic airflow difficulties;
7,8 and (2) its documented accept-
ability among these patients in longitudinal studies, which is
likely attributable to these 5 activities that each patient
selects.
8,9 Similarly, we had 3 reasons for selecting version 2.0
of the SF-36, which has eight scales, each having a 0–100
scoring range: physical functioning, roles affected by physical
health, bodily pain, general health, vitality, social functioning,
rolesaffectedmyemotionalhealth,andmental health.First,the
SF-36 is the most widely used HRQoL measure in the world.
10
Second, version 2.0 provides greater item comprehension and
improved measurement.
6 And third, use of this generic instru-
ment provides the potential for comparability of CIDs across
different diseases or conditions.
11
Our goal was to report and explicate the triangulated results
from evidence-based explorations to identify thresholds for the
MCID for HRQoL measures and for moderate and large CIDs.
Our triangulation investigation examined the perspectives of
three different groups with a stake in the management: a 9-
member expert panel of North American physicians familiar
with both the treatment of COPD patients and the measure-
ment of generic and COPD-specific HRQoL; outpatients with
COPD attending 2 Midwestern primary care clinics who
participated in bimonthly HRQoL evaluations over 1 year;
and the primary care physicians (PCPs) of these outpatients as
they followed their patients clinically over time.
Although several methods were previously proposed for this
purpose on interpreting HRQoL change in scores among
patient with COPD, none have adequately incorporated clini-
cians’ insight. Indeed, the seminal MCID investigation of
Jaeschke et al. reported on the use of a clinical consensus
panel to formulate hypothesized values of the MCID for the
dyspnea, fatigue, and emotional function domains of the
Chronic Heart Disease Questionnaire (CHQ) and the CRQ.
3
However, the only credential for panel membership was that
panelists had “extensive experience with their [CHQ and CRQ]
administration.” (p. 409) Therefore, our study was designed to
improve on that process by assembling an expert panel of
physicians who treat patients with COPD and are accom-
plished in their research on these patients’ HRQoL.
12
Moreover, the subsequent anchor-based MCID derivations in
the Jaeschke et al.
3 study did not ask the attending physician if
he/she concurred with the patient’s assessment of HRQoL
change. To move toward a community consensus, our triangu-
lation study collected both patient-reported changes and
evaluations of clinically significant change by the patients’
PCPs. Furthermore, we wanted to explore what changes in care
were associated with clinician-identified changes.
In addition, Jaeschke and colleagues averaged the absolute
values of change scores from patients declaring a minimal
improvement or decline in HRQoL to find the MCID. However, a
Figure 2. Chronic obstructive pulmonary disease (COPD) outpatient selection, enrollment, and participation.
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13 reported that these
HRQoL changes are not symmetrical, and patients who
reported getting worse had generally larger change scores than
those with similar improvements. As a result, we hoped to
improve on prior CRQ MCID studies by considering small,
moderate, and large improvements in separate analyses from
small, moderate, and large declines.
Finally, with the exception of expert panel reports,
12,14 no
known published studies have directly investigated CID
anchors and change scores for individuals on the SF-36 in
this disease group.
15 Therefore, our current study report is the
first known investigation that directly incorporates patients
and clinicians’ perceptions of important change to the SF-36
scales among patients with COPD.
METHODS
Expert Panel Processes
Figure 1 depicts our procedures for selecting and facilitating the
Delphi and consensus panel processes: a more detailed descrip-
tion can be found elsewhere.
12 In addition to working toward
consensus on the CID levels that represent small, moderate,
and large improvements and declines on the CRQ and SF-36
measures, this expert panel also successfully reached agree-
ment on the criteria for selection of appropriate outpatients with
COPD for our prospective study and advised us on the best
content wordings for items used to elicit these outpatients’
global assessments of change on each CRQ and SF-36 domain.
Chronic Obstructive Pulmonary Disease
Outpatients
Details of patient enrollment and participation are outlined in
Figure 2. First, the expert panel-derived criteria for potential
enrollment were applied to data in the electronic medical
records systems at Wishard Health Services in Indianapolis
and the St. Louis Veteran Affairs Medical Center. These criteria
are listed in the first box of Figure 2. The generality of these
potentially eligible criteria led to many patients being initially
selected (n=3,128). This electronic search cast the widest
administrative net for potential cases. When these patients’
PCPs reviewed these selected charts to confirm the potential
COPD diagnoses in their individual patients, far fewer COPD
cases (n=1,795) were identified. The patients thus identified
were interviewed for eligibility and interest in this study at
their next scheduled clinic visit, but many either refused to
participate or were deemed ineligible because they did not
know they had lung disease, did not have a phone in their
home, or could not hear well enough to use the telephone.
Interested and eligible participants signed informed consents.
Next, they provided enrollment data by answering several
Figure 3. Chronic obstructive pulmonary disease (COPD) primary care physician enrollment, confirmations, and baseline and follow-up
assessments.
164 Wyrwich et al.: Patient and Clinician Perspectives on HRQoL Change JGIMFigure 4. Global change assessment items for the Chronic Respiratory Disease Questionnaire (CRQ) domains and Medical Outcomes Study
Short Form 36-item survey (SF-36) scales.
165 Wyrwich et al.: Patient and Clinician Perspectives on HRQoL Change JGIMdemographic and comorbidity items, as well as selected the five
patient-specific activity items for the CRQ’s dyspnea domain.
Within 48 hours of their enrollment in the clinic, they were
contacted by telephone for their baseline HRQoL interviews.
The baseline interviews lasted on average of 35 minutes and
included the CRQ, the SF-36, the American Board of Internal
Medicine Patient Satisfaction Questionnaire,
16 the personal
stress scale from the National Opinion Research Council
National Health Survey,
17 a 5-item subset of the Medical
Outcomes Study social support scale,
18 Mirowsky and Ross’
sense of control measure,
19 the 2-summary religiosity and
spirituality items from the Fetzner instrument,
20 educational
attainment, employment status, perceived income adequacy,
and income. To assist our participants with recall at future
telephone interviews, we employed the use of memory markers
at the end of each interview that allowed participants to record
a significant or memorable aspect about their day (“I had lunch
with my sister Frances today”). This memory marker was then
read back to the participant at their next interview to assist
with the recall.
Subsequently, Louis Harris andAssociates conducted follow-
up telephone interviews every 2 months for a 1-year period
during which they readministered the CRQ and the SF-36, as
well as global assessments of change for each relevant dimen-
sion.However,ifduringtheyearanoutpatientvisitedthePCPat
least 1 month—but not more than 2 months—after a telephone
interview, this triggered an early follow-up telephone interview
within 72 hours after the PCP office visit. These visit-triggered
interviews were intended to capture the HRQoL of some out-
patients at a juncture when PCP assessments of disease-related
changes could also be obtained. Moreover, we hoped that many
of these early follow-up interviews would reflect extreme
fluctuations in HRQoL because of exacerbations that prompted
such PCP visits.
Primary Care Physicians
Forty-three PCPs at the Indianapolis
29 and the St. Louis
14 sites
volunteered to participate in this study as depicted in Figure 3.
By confirming disease eligibility; completing baseline evalua-
tions of disease severity; estimating the potential for hospital-
ization and mortality; and indicating referrals, tests, and
medication use, these PCPs provided necessary and direct
input from health care professionals both before and during
patient enrollments. If a patient participant returned for a
PCP office visit during the participant’s year of enrollment,
the PCP also assessed disease-related change over time so
that PCP-rated change could be directly compared (linked) to
the patients’ reports of change in their HRQoL. If the PCP
rated a participant to have a clinically significant change in
their COPD, the PCP was also prompted to evaluate the
change as an improvement or a decline; the magnitude of that
change (small, moderate, or large); and whether the change
resulted in a medication change, ordering laboratory test or
procedures, or a referral to a specialist. We provided no specific
definitions for the change assessments (no change; or small,
moderate,orlargeimprovementordecline),andeachparty(patient
andPCP)wasblindedtotheother’sassessment.
Statistical Procedures
We calculated each CRQ domain or SF-36 scale change scores
(time 2–time 1, where time 2=current follow up assessment
and time 1=immediately previous bimonthly assessment) for
each adjacent pair of completed interviews. The domain or
s c a l ec h a n g es c o r e sw e r et h e nc a t e g o r i z e db a s e do nt h e
patient’s transition rating index (TRI) for the dimension using
the global assessments of change in HRQoL that were included
in each follow-up interview. A complete list of the global
assessment items used for each of the 4 CRQ domains and
8 SF-36 scales are provided in Figure 4. If the participant
responded that he/she was better, we then asked him/her to
describe by how much better using a TRI of 1 (almost the
same, hardly any better) to 7 (a very great deal better).
Likewise, if the participant was worse, he/she provided a −1
(almost the same, hardly any worse) to −7 (a very great deal
worse) TRI. The TRI equaled 0 for those participants who
reported being “about the same.” The TRIs were classified
using the traditional approach described by Juniper et al.
21
and endorsed by Jaeschke et al. (Fig. 5).
Once classified into the appropriate change categories, we
determined the optimal thresholds for no change, and small,
moderate, and large improvements and declines for each
HRQoL measure by averaging all of the change scores within
a patient-perceived TRI classification.
3 We used the PCP’s
blinded assessment of change in the patient’s COPD because
the last linked clinical encounter in the same manner to
classify linked patient change scores in all HRQoL measures
before averaging (Fig. 3). All analyses were conducted using
SPSS, version 12.0.
22
Figure 5. Transition rating index for global estimates of change.
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After consideration of the panel’s premeeting Delphi activities,
each member of this expert panel was asked to articulate their
personal understandings of a clinically important change on
each CRQ domain and SF-36 scale at the face-to-face consen-
sus meeting. Panelists then agreed to calculate a unit of
measurement for each domain and scale named a state
change, which is equivalent to the amount of change in the
total score on most domain or scale items that results in
moving up just one response choice. Using the state change
metric, this North American physician expert panel reached
consensus on the CIDs for small, moderate, and large
improvements and declines (Table 1). State changes for the
CRQ dimensions were always 1 unit in magnitude, but the SF-
36 state changes varied from 5 to 12.5 units on the 0–100
scales. The expert panel recommended that small CID thresh-
olds were at least 2 state changes for all CRQ dimensions, and
at least 1 state change for each SF-36 scale. Although the
panel process was quite insightful, it is important to note that
our investigation had a priori designated the expert panel
CIDs, which would be the least important of the three
perspectives sampled in this study.
12
Table 2 presents the characteristics of our COPD outpatient
sample at baseline. These data reflect the considerable socio-
economic burdens this population faced, with one quarter
being self-identified minorities, over half never having com-
pleted high school, and two thirds reporting annual incomes
below $20,000. In addition, nearly all COPD enrollees had fair
or poor self-rated health, were either unable to work or had
retired, and had a smoking history of more than 20 pack years.
Of the 610 outpatients who completed baseline interviews, 554
(91%) completed their first follow-up interview 2 months later.
The 4-, 6-, 8-, 10-, and 12-month completion rates were 522
(86%), 504 (83%), 484 (79%), 462 (76%), and 462 (76%),
respectively, and demonstrated excellent cooperation from this
generally disadvantaged patient sample.
During the 2,988 follow-up interviews, most participants
(59–74%) reported no change or being about the same
compared to their prior interview when asked to make a global
assessment of change for each CRQ dimension and SF-36
scale (left-hand columns of Table 3). Of these 2,988 follow-up
interviews, 410 were linked to PCP office visits. Therefore, we
had both the patient’s assessment of change and the PCP’s
assessment of change in the patient’s COPD for these linked
interviews, which occurred mostly within 24 hours of the visit
with a maximum allowance of 72 hours between the visit and
the follow-up patient interview. Most PCPs (80%) reported no
change in the patient’s condition. As a result, there are few or
no patient/PCP-linked encounters identifying either improve-
Table 1. Recommendations for Small, Moderate, and Large
Change Thresholds on the Chronic Respiratory Disease
Questionnaire (CRQ) and Medical Outcomes Study Short Form 36-
Item Survey (SF-36), Version 2.0 by the North American Physician
Expert Panel
HRQoL
measure
Value
of one
state
change
Number
of items
Small
change
Moderate
change
Large
change
CRQ
Dyspnea 1 5 3 6 9
Fatigue 1 4 2 4 6
Emotional 1 7 5 10 15
Mastery 1 4 3 6 9
SF-36
Physical
functioning
51 0 1 0 2 0 3 0
Role physical 6.25 4 12.5 25 37.5
Bodily pain 10 2 10 20 30
General health 5 5 10 20 30
Vitality 6.25 4 12.5 25 37.5
Social
functioning
12.5 2 12.5 25 37.5
Role emotional 8.33 3 8.33 16.67 25
Mental health 5 5 10 20 30
The panel reached consensus that, in the absence of evidence to the
contrary, all of the thresholds were symmetrical (i.e., improvement and
decline magnitudes were equivalent).
Table 2. Baseline Demographics and Health Characteristics among
Patients with Chronic Obstructive Pulmonary Disease (COPD)
Attending Midwest Medical Centers (August 2000–November 2001)
COPD outpatients, N (%) or mean
Age
50–54 70 (11.5)
55–64 195 (32.0)
65–74 228 (37.4)
>75 117 (19.2)
Sex
Female 217 (35.6)
Male 393 (64.4)
Race
White 467 (76.6)
Black 128 (21.0)
Other 14 (2.3)
Unknown 1 (0.2)
Education
<High school 341 (55.9)
High school 150 (24.6)
>High school 118 (19.3)
Unknown 1 (0.2)
Annual household income
<10,000 150 (24.6)
10,000–14,999 138 (22.6)
15,000–19,999 127 (20.8)
20,000–24,999 84 (13.8)
≥$25,000 81 (13.3)
Unknown 30 (4.9)
Employment status
Employed for wages 63 (10.3)
Unable to work 246 (40.3)
Retired 267 (43.8)
Others 34 (5.6)
Patient-reported general health
Excellent 8 (1.3)
Very good 35 (5.7)
Good 118 (19.3)
Fair 241 (39.5)
Poor 208 (34.1)
Smoking status
Never 37 (6.1)
<20 pack y 157 (25.7)
≥20 pack y 409 (67.0)
Unknown 7 (1.1)
Sense of control* 18.7
Religiosity
† 63.9
Social support
† 64.5
Stress
† 55.9
Patient satisfaction
† 81.7
*Ranges from 0 (denies responsibility) to 100 (takes responsibility).
†Transformed from 0=worst (least religious, lowest support, most stress,
and least satisfaction) to 100=best.
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weighted kappa statistics for agreement
23 between patient-
reported changes among those with linked PCP assessment
and the associated PCP assessments of change ranged from
0.29 (dyspnea domain of the CRQ) to 0.07 (role emotional scale
of the SF-36), demonstrating poor agreement among these
linked raters.
Forthe 80clinicalencounterswhena PCP reporteda clinically
significant change, half (n=40) were coupled with a change in
medication. Of these, most often (n=37) the PCP stated that
there had been a decline in the participant’s COPD. Few linked
PCP encounters with clinically significant changes resulted in
ordering laboratory tests or procedures (n=16) or referral to a
specialist (n=5), but nearly all of the patients requiring these
changes in care had a PCP-rated decline in their condition.
Table 4 reports the mean thresholds, respectively, for the
change scores (time 2–time 1) of the patients classified into
each cell of Table 3. With few exceptions, the CRQ measures
were able to detect small changes at levels reported by the
patients and their PCPs. This is evidenced by the patient-
perceived small decline thresholds being 1–2 points (equivalent
to 1 or 2 state changes), and the optimal small improvement
thresholds for both patients and PCPs being 1–5 points. An
exception involves the CRQ mastery dimension and small
improvements rated by PCPs, and there is prior corroboration
that longitudinal validity is problematic for this domain.
5
Patient-perceived moderate and large improvements and
declines also seem credible, again with the exception of the
mastery domain. The PCP-perceived average change scores for
those with clinically significant declines do not display trends
seen in the patient-perceived results, and PCP-related moder-
ate improvement thresholds for dyspnea and mastery are
somewhat uninterruptible given the no change and small
improvement results.
In contrast, the SF-36 results are more problematic because
small changes rated by patients or their PCPs yielded average
change thresholds that were generally smaller than one state
change value (which range from 5 to 12.5, see Table 1)f o rt h eS F -
36 scales. It is counterintuitive to recommend that an important
change has happened when a threshold is at a level less than the
resulting scale scores change that occurs when an individual
shifts to an adjacent response category on only one item in a
scale.
12,14 Our SF-36 results demonstrate that among the small
improvement and decline thresholds, only the patient-perceived
changes in mental health (small decline) and role physical (small
improvement), and the PCP-classified changes for physical
functioning, role physical, and general health (small improve-
ment) meet this “at least one state change” criterion. Although
some moderate and large change category thresholds do meet the
state change criterion, many do not and it is difficult to interpret
trends in many of the SF-36 scale results.
DISCUSSION
The results of our triangulation investigation provide several
“off the shelf” CIDs for the CRQ domains when used to
benchmark important changes in HRQoL domains in similar
patient populations. In so doing, they also serve as a procedural
outline for future multiple stakeholder studies to determine
CIDs in other HRQoL measures and/or other patient popula-
tions, as well as an insight to the complications that occur when
T
a
b
l
e
3
.
S
a
m
p
l
e
S
i
z
e
(
P
e
r
c
e
n
t
a
g
e
s
)
w
i
t
h
i
n
C
h
a
n
g
e
C
a
t
e
g
o
r
i
z
a
t
i
o
n
s
b
y
P
a
t
i
e
n
t
a
n
d
P
r
i
m
a
r
y
C
a
r
e
P
h
y
s
i
c
i
a
n
(
P
C
P
)
R
e
p
o
r
t
s
o
f
C
h
a
n
g
e
o
n
t
h
e
C
h
r
o
n
i
c
R
e
s
p
i
r
a
t
o
r
y
D
i
s
e
a
s
e
Q
u
e
s
t
i
o
n
n
a
i
r
e
(
C
R
Q
)
D
o
m
a
i
n
s
a
n
d
M
e
d
i
c
a
l
O
u
t
c
o
m
e
s
S
t
u
d
y
S
h
o
r
t
F
o
r
m
3
6
-
I
t
e
m
S
u
r
v
e
y
(
S
F
-
3
6
)
S
c
a
l
e
s
H
R
Q
o
L
m
e
a
s
u
r
e
P
a
t
i
e
n
t
-
p
e
r
c
e
i
v
e
d
c
h
a
n
g
e
s
P
C
P
-
p
e
r
c
e
i
v
e
d
c
h
a
n
g
e
s
L
a
r
g
e
d
e
c
l
i
n
e
M
o
d
e
r
a
t
e
d
e
c
l
i
n
e
S
m
a
l
l
d
e
c
l
i
n
e
N
o
c
h
a
n
g
e
S
m
a
l
l
i
m
p
r
o
v
e
M
o
d
e
r
a
t
e
i
m
p
r
o
v
e
L
a
r
g
e
i
m
p
r
o
v
e
L
a
r
g
e
d
e
c
l
i
n
e
M
o
d
e
r
a
t
e
d
e
c
l
i
n
e
S
m
a
l
l
d
e
c
l
i
n
e
N
o
c
h
a
n
g
e
S
m
a
l
l
i
m
p
r
o
v
e
M
o
d
e
r
a
t
e
i
m
p
r
o
v
e
L
a
r
g
e
i
m
p
r
o
v
e
C
R
Q
D
y
s
p
n
e
a
1
2
1
(
4
)
1
9
8
(
7
)
3
1
3
(
1
1
)
1
,
8
0
7
(
6
3
)
2
1
2
(
7
)
1
6
2
(
6
)
6
8
(
2
)
3
(
1
)
2
3
(
6
)
2
8
(
7
)
3
1
1
(
8
0
)
1
5
(
4
)
8
(
2
)
0
(
0
)
E
m
o
t
i
o
n
a
l
7
0
(
2
)
1
3
3
(
5
)
2
0
8
(
7
)
1
,
8
5
0
(
6
4
)
2
6
6
(
9
)
2
4
0
(
8
)
1
1
5
(
4
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
F
a
t
i
g
u
e
9
3
(
3
)
1
7
1
(
6
)
3
4
9
(
1
2
)
1
,
8
6
7
(
6
5
)
1
9
7
(
7
)
1
5
2
(
5
)
5
4
(
2
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
M
a
s
t
e
r
y
5
2
(
2
)
8
2
(
3
)
1
5
8
(
5
)
2
,
0
5
3
(
7
1
)
2
4
7
(
9
)
1
9
6
(
7
)
9
6
(
3
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
S
F
-
3
6
P
h
y
s
i
c
a
l
f
u
n
c
t
i
o
n
i
n
g
1
0
9
(
4
)
2
1
6
(
8
)
2
4
2
(
8
)
1
,
9
4
4
(
6
8
)
1
8
8
(
7
)
1
3
2
(
5
)
4
9
(
2
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
R
o
l
e
p
h
y
s
i
c
a
l
1
1
1
(
4
)
1
9
0
(
7
)
2
8
4
(
1
0
)
2
,
0
0
7
(
7
0
)
1
3
9
(
5
)
1
1
0
(
4
)
4
2
(
1
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
B
o
d
i
l
y
p
a
i
n
1
3
5
(
5
)
2
7
4
(
1
0
)
3
1
4
(
1
1
)
1
,
7
9
0
(
6
2
)
1
4
4
(
5
)
1
4
6
(
5
)
7
5
(
3
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
G
e
n
e
r
a
l
h
e
a
l
t
h
1
1
2
(
4
)
2
1
4
(
7
)
4
0
6
(
1
4
)
1
,
6
9
8
(
5
9
)
2
1
8
(
8
)
1
5
4
(
5
)
7
0
(
2
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
V
i
t
a
l
i
t
y
1
1
3
(
4
)
2
1
9
(
8
)
3
6
8
(
1
3
)
1
,
7
7
8
(
6
2
)
1
9
9
(
7
)
1
5
0
(
5
)
5
7
(
2
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
S
o
c
i
a
l
f
u
n
c
t
i
o
n
i
n
g
1
1
5
(
4
)
1
5
2
(
5
)
2
0
0
(
7
)
2
,
1
1
0
(
7
4
)
1
2
2
(
4
)
1
1
7
(
4
)
4
6
(
2
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
R
o
l
e
e
m
o
t
i
o
n
a
l
7
0
(
2
)
1
3
3
(
5
)
2
0
8
(
7
)
2
,
1
3
2
(
7
4
)
1
5
0
(
5
)
1
2
6
(
4
)
5
9
(
2
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
M
e
n
t
a
l
h
e
a
l
t
h
6
4
(
2
)
1
1
8
(
4
)
1
9
5
(
7
)
2
,
0
3
1
(
7
1
)
1
8
1
(
6
)
1
8
5
(
6
)
9
8
(
3
)
3
(
1
)
2
3
(
6
)
3
0
(
7
)
3
3
0
(
8
0
)
1
5
(
4
)
9
(
2
)
0
(
0
)
168 Wyrwich et al.: Patient and Clinician Perspectives on HRQoL Change JGIMthree streams of data to not converge. Beyond these products,
our results also demonstrate 2 previously documented HRQoL
measurement issues: (1) the merits of disease-specific mea-
sures for monitoring individual HRQoL change;
24,25 and (2) the
gap between expert panelists, patients, and their PCPs’ percep-
tions of change
26,27 in individual patients.
Replicating our findings in COPD populations that differ from
our sample is important to determine the generalizability of our
CID results to this disease group. Our expert panel’sr e s u l t s
matched the 1989 CHQ/CRQ clinical consensus panel recom-
mendations.
5 Our patient-perceived thresholds are similar, and
insomedomains, a bit lower than those ascertained byJaeschke
and colleagues’ pioneering HRQoL interpretation study.
5
Despite our substantial sample size (n=610 at baseline),
there was a limited number of PCP-reported improvements (n=
24) or declines (n=56) in HRQoL among these outpatients over
a year of enrollment, with no PCP reporting a large improve-
ment. The scarcity of change scores available for the PCP-
classified CID estimates not only questions their stability, but
also underscores the need for very large (if not prohibitive)
sample sizes to observe a substantial number of improvements
or declines within small time intervals. In addition, there was
poor agreement between the patient and PCP assessments of
change, especially in these problematic cells.
These results provide investigators with benchmarks for
evaluating patient-reported changes in HRQoL using these
measures with COPD patients. Hence, they are a valuable
resource for future interventions with primary and secondary
HRQoL outcomes, demonstrating not just a statistically sig-
nificant difference but also a clinically significant difference in
patient change, which is currently recommended by the FDA
for patient-reported outcome measures. Nonetheless, there are
important limitations to these results. First, because of busy
clinic schedules, we did not ask PCPs to rate their perceived
changes in each HRQoL domain and scale at all linked patient
encounters; instead, we asked PCPs to evaluate whether the
participant had a clinically significant change in their COPD.
Therefore, it is possible that patients and PCPs were rating
different constructs. Yet, even the most COPD-related CRQ
dyspnea domain, which assessed change in activities affected
by shortness of breath, yielded a dismal weighted kappa value
(κ=.29) when compared to the PCPs’ COPD change rating
among linked patients. The poor agreement in statistics are
numerically affected by the overwhelming number of patients
in the “no change” category, but nonetheless demonstrate a
need for increased dialogue between patients and physicians
regarding when important changes occur.
We hoped that our PCP ratings of clinically significant
changes in COPD would also be documented through changes
in care. Of the 80 encounters where PCPs did note a change, 47
of these were associated with a positive response to at least one
change in care item. Moreover, most of the patients who had a
clinically significant PCP change rating but no reported change
in care action were rated as improved. Although we recognize
instances where an important change in condition may not
require a change in care, we encourage other researchers
interested in documenting clinicians’ assessments of change
to also explore treatment responses to these evaluations.
28
Another limitation in this field of inquiry is the retrospective
global change assessments that anchor the patients’ change
classifications. Several studies have demonstrated that
patients have great difficulty in accurately remembering their
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169 Wyrwich et al.: Patient and Clinician Perspectives on HRQoL Change JGIMprior health state (time 1) and then comparing it to their
current health (time 2).
29–31 As a result, the change assess-
ments are often highly correlated with current health, and
uncorrelated with the time 1 assessment. To assist with this
recall, we employed the use of memory markers to potentially
improve the accuracy of the anchor-based methodology.
Nonetheless, the use of these single-item global assessments
to classify change in a domain measured through multiple
items at each time point may be intuitively flawed, despite the
fact that it does reflect the patient’s overall perceptions of
HRQoL changes. This ambiguity deserves further investigation
that may necessitate improved patient-reported anchors. In
addition, there is a potential problem of response shift
32 from
changes in patients or PCPs understanding of conceptualiza-
tion of (1) the domain or scale being assessed over their
enrollment span; or (2) the response options used with the
HRQoL instruments, the TRIs, or the PCP assessments.
Our findings have implications for clinical research, as
suggested by the FDA’s call for community consensus, and for
clinical practice. In these data, patients tend to report smaller
changes as more clinically meaningful than do physicians.
Conversely, physicians may look for changes of a magnitude
that warrant clinical actions or show unquestionable improve-
ments. The demonstrated disconnection between these two
perspectives in achieving agreement regarding who has
changed and thelevel ofimportant change is needed. Integrating
both patient and physician perspectives is important to improve
research applications and interpretation of these important
outcomes,
33 and patient–physician communications regarding
health status, treatment options, and shared decision making
for living with chronic disease like COPD.
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